Woippy, the 14th of November at 8:00 am – ABL Diagnostics (Euronext Paris: ABLD), a French company specializing in advanced molecular diagnostics, announces the signing of an exclusive distribution agreement with Eurobio Scientific (Euronext Growth Paris: ALERS, ISIN FR0013240934), a leading in vitro diagnostics company, for the commercialization of its VELA product line within a defined segment of the French public hospital market.
Effectively, this agreement aims to enhance access to ABL Diagnostics’ next-generation sequencing (NGS) and viral genotyping solutions, while ensuring optimal local service for end users.
A targeted collaboration to enhance customer service
Under the agreement:
• A list of existing customers will be transferred to Eurobio Scientific, which will manage their commercial, logistical, and first-line technical support;
• Other customers will continue to be managed directly by ABL Diagnostics, ensuring continuity and high-level technical expertise.
This differentiated approach enables optimized market coverage while maintaining a high standard of service for healthcare professionals and patients.
A logical continuation with a long-standing partner
Eurobio Scientific has historically distributed the VELA product line in France and several European countries, prior to its integration into ABL Diagnostics’ portfolio.
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer